MedTrace Logo

GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)

NCT05182567 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2023-09-13

No results posted yet for this study

Summary

Phase I study to assess the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine given as a booster to those previously vaccinated against SARS-CoV-2

Conditions

Interventions

DRUG

GLS-5310 (Group 1)

GLS-5310 DNA plasmid vaccine

DRUG

GLS-5310 (Group 2)

GLS-5310 DNA plasmid vaccine

DRUG

GLS-5310 (Group 3)

GLS-5310 DNA plasmid vaccine

DRUG

GLS-5310 (Group 4)

GLS-5310 DNA plasmid vaccine

Sponsors & Collaborators

  • GeneOne Life Science, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-23
Primary Completion
2023-01-10
Completion
2023-12-31
FDA Drug
Yes

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05182567 on ClinicalTrials.gov